• Trade
  • Markets
  • Copy
  • Contests
  • News
  • 24/7
  • Calendar
  • Q&A
  • Chats
Screeners
SYMBOL
LAST
ASK
BID
HIGH
LOW
NET CHG.
%CHG.
SPREAD
SPX
S&P 500 Index
6882.71
6882.71
6882.71
6936.08
6838.79
-35.10
-0.51%
--
DJI
Dow Jones Industrial Average
49501.29
49501.29
49501.29
49649.86
49112.43
+260.29
+ 0.53%
--
IXIC
NASDAQ Composite Index
22904.57
22904.57
22904.57
23270.07
22684.51
-350.61
-1.51%
--
USDX
US Dollar Index
97.630
97.710
97.630
97.750
97.470
+0.150
+ 0.15%
--
EURUSD
Euro / US Dollar
1.17911
1.17919
1.17911
1.18086
1.17800
-0.00134
-0.11%
--
GBPUSD
Pound Sterling / US Dollar
1.36025
1.36037
1.36025
1.36537
1.35563
-0.00494
-0.36%
--
XAUUSD
Gold / US Dollar
4885.37
4885.71
4885.37
5023.58
4788.42
-80.19
-1.61%
--
WTI
Light Sweet Crude Oil
64.181
64.211
64.181
64.362
63.245
-0.061
-0.09%
--

Community Accounts

Signal Accounts
--
Profit Accounts
--
Loss Accounts
--
View More

Become a signal provider

Sell trading signals to earn additional income

View More

Guide to Copy Trading

Get started with ease and confidence

View More

Signal Accounts for Members

All Signal Accounts

Best Return
  • Best Return
  • Best P/L
  • Best MDD
Past 1W
  • Past 1W
  • Past 1M
  • Past 1Y

All Contests

  • All
  • Trump Updates
  • Recommend
  • Stocks
  • Cryptocurrencies
  • Central Banks
  • Featured News
Top News Only
Share

Central Bank Data - Foreign Investors' Turkish Government Bonds $+721.8 Million Of In Week To January 30

Share

Central Bank Data - Foreign Investors' Turkish Stocks $+455.0 Million

Share

Central Bank Data - Forex Held By Turkish Locals Stood At $238.25 Billion As Of January 30, From $230.99 Billion A Week Earlier

Share

ICE New York Cocoa Gains More Than 3% To $4223 A Metric Ton

Share

ICE London Cocoa Gains Nearly 4% To 3083 Pounds A Metric Ton

Share

Egypt's M2 Money Supply 20.5 % Year-On-Year In December

Share

Turkish Energy Minister: Turkey's Tpao Signed Memorandum Of Understanding With Chevron On Possible Energy Cooperation

Share

Egypt's Net Foreign Reserves Rise To $52.594 Billion In January From $51.452 Billion In December

Share

Moody's: Indonesia's Outlook Change Reflects Low Predictability In Policymaking

Share

Russia Is Open To International Cooperation On Zaporizhzhia Nuclear Plant, Including With The USA, But The Plant Must Be Russian - Tass Cites Likhachev

Share

UBS's Investment Banking Divisions Reportedly Increased Their Bonus Pools By 20% In 2025

Share

Spain's Prime Minister Sanchez: Techoligarchs Won't Sway US Over Social Media Ban

Share

Irish Unemployment Rate +4.7% In Jan And Revised To +4.7% In Dec (Previous +5.0%)

Share

Iran's Revolutionary Guards Detain Two Vessels In The Gulf Carrying Over 1 Million Liters Of Smuggled Fuel, Crew Of 15 Foreigners Referred To Judiciary

Share

Shanghai International Energy Exchange: To Raise Price Limits, Margin Ratios For International Copper Futures Contracts From Feb 9 Closing Settlement

Share

German Chancellor Merz: Discussed Human Rights During Gulf Trip But Those Talks Remain Behind Closed Doors

Share

China's Foreign Ministry Official To Iran Diplomat: China Supports Iran's Legitimate Right To Peaceful Uses Of Nuclear Energy

Share

German Chancellor Merz: Concern About Military Escalation In Middle East Is Big, We Want To Contribute To Iran Stopping Its Destabilising Behaviour

Share

Vattenfall: Swedish Nuclear Plans Need Direct State Investment

Share

[Should Trump Also Testify Before Congress On The Epstein Case? US House Speaker Responds] According To CNN, On The 4th, Its Reporter Asked US House Speaker Mike Johnson, A Republican, About The Epstein Case: "Would Subpoenaing The Clintons Set A Precedent? If The Democrats Have A Majority In The House, They Might Subpoena The Current President Or Other Former Presidents, And Perhaps Trump Would Also Have To Testify?" Johnson Responded That Subpoenaing The Clintons Was "well Justified," And Said That Trump Has Been "responding To Media Inquiries Every Day" On These Issues

TIME
ACT
FCST
PREV
Brazil IHS Markit Services PMI (Jan)

A:--

F: --

P: --

U.S. ADP Employment (Jan)

A:--

F: --

P: --
The U.S. Treasury Department released its quarterly refinancing statement.
U.S. IHS Markit Composite PMI Final (Jan)

A:--

F: --

P: --

U.S. IHS Markit Services PMI Final (Jan)

A:--

F: --

P: --

U.S. ISM Non-Manufacturing Price Index (Jan)

A:--

F: --

P: --

U.S. ISM Non-Manufacturing Employment Index (Jan)

A:--

F: --

P: --

U.S. ISM Non-Manufacturing New Orders Index (Jan)

A:--

F: --

P: --

U.S. ISM Non-Manufacturing Inventories Index (Jan)

A:--

F: --

P: --

U.S. ISM Non-Manufacturing PMI (Jan)

A:--

F: --

P: --

U.S. EIA Weekly Crude Oil Imports Changes

A:--

F: --

P: --

U.S. EIA Weekly Heating Oil Stock Changes

A:--

F: --

P: --

U.S. EIA Weekly Crude Demand Projected by Production

A:--

F: --

P: --

U.S. EIA Weekly Gasoline Stocks Change

A:--

F: --

P: --

U.S. EIA Weekly Crude Stocks Change

A:--

F: --

P: --

U.S. EIA Weekly Cushing, Oklahoma Crude Oil Stocks Change

A:--

F: --

P: --

Australia Trade Balance (SA) (Dec)

A:--

F: --

P: --
Australia Exports MoM (SA) (Dec)

A:--

F: --

P: --
Japan 30-Year JGB Auction Yield

A:--

F: --

P: --

Indonesia Annual GDP Growth

A:--

F: --

P: --

Indonesia GDP YoY (Q4)

A:--

F: --

P: --

France Industrial Output MoM (SA) (Dec)

A:--

F: --

P: --
Italy IHS Markit Construction PMI (Jan)

A:--

F: --

P: --

Euro Zone IHS Markit Construction PMI (Jan)

A:--

F: --

P: --

Germany Construction PMI (SA) (Jan)

A:--

F: --

P: --

Italy Retail Sales MoM (SA) (Dec)

A:--

F: --

P: --

U.K. Markit/CIPS Construction PMI (Jan)

A:--

F: --

P: --

France 10-Year OAT Auction Avg. Yield

A:--

F: --

P: --

Euro Zone Retail Sales YoY (Dec)

A:--

F: --

P: --
Euro Zone Retail Sales MoM (Dec)

A:--

F: --

P: --
U.K. BOE MPC Vote Cut (Feb)

--

F: --

P: --

U.K. BOE MPC Vote Hike (Feb)

--

F: --

P: --

U.K. BOE MPC Vote Unchanged (Feb)

--

F: --

P: --

U.K. Benchmark Interest Rate

--

F: --

P: --

MPC Rate Statement
U.S. Challenger Job Cuts (Jan)

--

F: --

P: --

U.S. Challenger Job Cuts MoM (Jan)

--

F: --

P: --

U.S. Challenger Job Cuts YoY (Jan)

--

F: --

P: --

Bank of England Governor Bailey held a press conference on monetary policy.
Euro Zone ECB Marginal Lending Rate

--

F: --

P: --

Euro Zone ECB Deposit Rate

--

F: --

P: --

Euro Zone ECB Main Refinancing Rate

--

F: --

P: --

ECB Monetary Policy Statement
U.S. Weekly Initial Jobless Claims (SA)

--

F: --

P: --

U.S. Initial Jobless Claims 4-Week Avg. (SA)

--

F: --

P: --

U.S. Weekly Continued Jobless Claims (SA)

--

F: --

P: --

ECB Press Conference
U.S. JOLTS Job Openings (SA) (Dec)

--

F: --

P: --

U.S. EIA Weekly Natural Gas Stocks Change

--

F: --

P: --

BOC Gov Macklem Speaks
Mexico Policy Interest Rate

--

F: --

P: --

U.S. Weekly Treasuries Held by Foreign Central Banks

--

F: --

P: --

Reserve Bank of Australia Governor Bullock testified before Parliament.
India Benchmark Interest Rate

--

F: --

P: --

India Cash Reserve Ratio

--

F: --

P: --

India Repo Rate

--

F: --

P: --

India Reverse Repo Rate

--

F: --

P: --

Japan Leading Indicators Prelim (Dec)

--

F: --

P: --

Germany Industrial Output MoM (SA) (Dec)

--

F: --

P: --

Germany Exports MoM (SA) (Dec)

--

F: --

P: --

U.K. Halifax House Price Index YoY (SA) (Jan)

--

F: --

P: --

Q&A with Experts
    • All
    • Chatrooms
    • Groups
    • Friends
    SlowBear ⛅ flag
    Nawhdir Øt
    @Nawhdir Øt yes you sure have been you left almost everything to focus on btc intraday trades
    SlowBear ⛅ flag
    Nawhdir Øt
    @Nawhdir Øt I see that, wait you closed your buy on Gold already? Or you still holding?
    SlowBear ⛅ flag
    Nawhdir Øt
    Oh yeah, Tesla, I don't understand anymore. Even though I've researched the report and combined the technical aspects, the price is still below the entry price.
    @Nawhdir Øt the price of Tesla is below entry price? That is interesting I am still go holding Tesla since June 2025 they we discussed about it with Netflix to remember?
    SlowBear ⛅ flag
    I only just joined Appl on Monday this week and it’s left alone to do its things
    Nawhdir Øt flag
    SlowBear ⛅
    Trading around $407.45, TSLA reached an intraday high of $423.90 and a low of $399.18 on February 5, 2026, with a trading volume of 74.61 million shares. Its market cap of $1.52 trillion and P/E ratio of 392.37 indicate a high valuation despite a -2.9% year-over-year revenue decline to $94.83 billion.
    Nawhdir Øt flag
    SlowBear ⛅
    @SlowBear ⛅if that's what I remember
    Nawhdir Øt flag
    SlowBear ⛅
    @SlowBear ⛅when? I haven't traded gold /today
    Nawhdir Øt flag
    Tesla EV sales to decline for two consecutive years in 2025,
    SlowBear ⛅ flag
    Nawhdir Øt
    @Nawhdir Øt oh so that is interesting, and you are still not interested in jumping in?
    SlowBear ⛅ flag
    Nawhdir Øt
    @Nawhdir Øt i meant the 42XX you were holding since last year
    SlowBear ⛅ flag
    Nawhdir Øt
    @Nawhdir Øt oh okay that was a while ago I guess, but again there is always a new opportunity for you to join
    Nawhdir Øt flag
    SlowBear ⛅
    @SlowBear ⛅Technical Analysis: The short-term trend is neutral with a 14-day RSI of 36.98 (sell signal), but the long-term trend is bullish above the 200-day MA of $379.79. Stochastic is oversold (17.82%), MACD is a buy signal, and historical volatility is 40%+.
    Nawhdir Øt flag
    SlowBear ⛅ flag
    Nawhdir Øt
    Tesla EV sales to decline for two consecutive years in 2025,
    @Nawhdir Øt but the stocks seems to have gotten elevated since that
    Nawhdir Øt flag
    SlowBear ⛅
    @SlowBear ⛅THAT'S it, that's why I bought.
    SlowBear ⛅ flag
    Nawhdir Øt
    @Nawhdir Øt which instrument is this analysis is based off on bro
    Nawhdir Øt flag
    When data showed a decline in stocks, I immediately looked at the technical analysis to enter at the lowest possible price.
    Nawhdir Øt flag
    SlowBear ⛅
    @SlowBear ⛅still Tesla
    Nawhdir Øt flag
    you know, I'm focused on Tesla's Q1
    SlowBear ⛅ flag
    Nawhdir Øt
    @Nawhdir Øt oh okay that is decent I will have a look at it when the stock market open, to see if I can get an entry
    Type here...
    Add Symbol or Code

      No matching data

      All
      Trump Updates
      Recommend
      Stocks
      Cryptocurrencies
      Central Banks
      Featured News
      • All
      • Russia-Ukraine Conflict
      • Middle East Flashpoint
      • All
      • Russia-Ukraine Conflict
      • Middle East Flashpoint
      Search
      Products

      Charts Free Forever

      Chats Q&A with Experts
      Screeners Economic Calendar Data Tools
      Membership Features
      Data Warehouse Market Trends Institutional Data Policy Rates Macro

      Market Trends

      Market Sentiment Order Book Forex Correlations

      Top Indicators

      Charts Free Forever
      Markets

      News

      News Analysis 24/7 Columns Education
      From Institutions From Analysts
      Topics Columnists

      Latest Views

      Latest Views

      Trending Topics

      Top Columnists

      Latest Update

      Signals

      Copy Rankings Latest Signals Become a signal provider AI Rating
      Contests
      Brokers

      Overview Brokers Assessment Rankings Regulators News Claims
      Broker listing Forex Brokers Comparison Tool Live Spread Comparison Scam
      Q&A Complaint Scam Alert Videos Tips to Detect Scam
      More

      Business
      Events
      Careers About Us Advertising Help Center

      White Label

      Broker API

      Data API

      Web Plug-ins

      Affiliate Program

      Awards Institution Evaluation IB Seminar Salon Event Exhibition
      Vietnam Thailand Singapore Dubai
      Fans Party Investment Sharing Session
      FastBull Summit BrokersView Expo
      Recent Searches
        Top Searches
          Markets
          News
          Analysis
          User
          24/7
          Economic Calendar
          Education
          Data
          • Names
          • Latest
          • Prev

          View All

          No data

          Scan to Download

          Faster Charts, Chat Faster!

          Download App
          English
          • English
          • Español
          • العربية
          • Bahasa Indonesia
          • Bahasa Melayu
          • Tiếng Việt
          • ภาษาไทย
          • Français
          • Italiano
          • Türkçe
          • Русский язык
          • 简中
          • 繁中
          Open Account
          Search
          Products
          Charts Free Forever
          Markets
          News
          Signals

          Copy Rankings Latest Signals Become a signal provider AI Rating
          Contests
          Brokers

          Overview Brokers Assessment Rankings Regulators News Claims
          Broker listing Forex Brokers Comparison Tool Live Spread Comparison Scam
          Q&A Complaint Scam Alert Videos Tips to Detect Scam
          More

          Business
          Events
          Careers About Us Advertising Help Center

          White Label

          Broker API

          Data API

          Web Plug-ins

          Affiliate Program

          Awards Institution Evaluation IB Seminar Salon Event Exhibition
          Vietnam Thailand Singapore Dubai
          Fans Party Investment Sharing Session
          FastBull Summit BrokersView Expo

          HeartBeam (NASDAQ: BEAT) Appoints Bryan Humbarger as Chief Commercial Officer

          FinanceWire
          HeartBeam
          -3.47%
          Heartbeam, Inc. Warrant
          +3.23%

          Austin, Texas, United States, January 22nd, 2026, FinanceWire

          HeartBeam , a medical technology company focused on advancing cardiac care through actionable cardiac insights, announced the appointment of Bryan Humbarger as chief commercial officer, effective Jan. 22, 2026. In the newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives, including the limited launch of the recently cleared HeartBeam System for arrhythmia assessment, heart attack detection indication and a 12-lead ECG extended wear patch monitor, while expanding outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption.

          To view the full press release, visit https://ibn.fm/9YzeT

          About HeartBeam, Inc.

          HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 2025*.

          *Cleared Indications for Use

          The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.

          NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

          Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

          The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

          Contact

          IBN

          512.354.7000 Office

          www.InvestorBrandNetwork.com

          Editor@InvestorBrandNetwork.com

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          FDA Clearance for HeartBeam (NASDAQ: BEAT) Highlighted in Medical Device Approvals Roundup

          FinanceWire
          HeartBeam
          -3.47%
          Heartbeam, Inc. Warrant
          +3.23%

          Austin, Texas, United States, January 12th, 2026, FinanceWire

          HeartBeam  was among the medical device companies highlighted in a Jan. 8 report by Modern Healthcare by Lauren Dubinsky that outlined FDA clearances and approvals across the medical device sector. HeartBeam’s 12-lead electrocardiogram synthesis software was cleared Dec. 8 to assess arrhythmias by converting heart signal data captured from 3 dimensions using the company’s portable, non-invasive recorder into a standard 12-lead ECG format suitable for remote clinical review.

          HeartBeam recently reinforced its technology leadership with recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide and trailing only GE Healthcare, in 12-lead ECG innovation among 243 companies evaluated in PatentVest’s “Total Cardiac Intelligence” report, according to an InvestorBrandNetwork report. The ranking reflects the strength of its intellectual-property foundation, with 82 global patent publications across 15 patent families supporting its three-dimensional cardiac signal capture and 12-lead ECG synthesis architecture, underscoring the company’s growing influence in next-generation remote cardiac monitoring.

          To learn more about Heartbeam’s Portable ECG Technology, visit https://ibn.fm/pfPB1

          About HeartBeam, Inc.

          HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 2025. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.

          NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

          Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

          The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

          Contact

          IBN

          www.InvestorBrandNetwork.com

          Editor@InvestorBrandNetwork.com

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          HeartBeam (NASDAQ: BEAT) to Attend JP Morgan 2026 Annual Healthcare Conference

          FinanceWire
          HeartBeam
          -3.47%
          Heartbeam, Inc. Warrant
          +3.23%

          Austin, Texas, United States, January 5th, 2026, FinanceWire

          HeartBeam , a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place Jan. 12–15, 2026, at the Westin St. Francis Hotel in San Francisco, where Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will be available Jan. 12–14 for off-site meetings with investors and potential commercialization and co-development partners. Discussions are expected to focus on the company’s recently announced 510(k) clearance from the U.S. Food and Drug Administration for its patented, cable-free 12-lead electrocardiogram synthesis software for arrhythmia assessment, ahead of a planned limited U.S. commercial launch in Q1 2026.

          To view the full press release, visit https://nnw.fm/zvmUc

          About HeartBeam, Inc.

          HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com

          (1) Cleared Indications for Use

          The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient’s 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional.

          The HeartBeam 12-Lead ECG Synthesis Software synthesizes a 12-Lead ECG from the HeartBeam System 3-Leads (in three-directions) recording device, producing a visual 12-Lead ECG representation that is similar, but not identical, to the same leads of a standard diagnostic 12-Lead ECG. The synthesized 12-Lead ECG output is solely intended for manual assessment of normal sinus rhythm and the following non-life-threatening arrhythmias: sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex. The synthesized 12-Lead ECG output is not intended for the assessment of any other arrhythmia or conditions (including but not limited to: other atrial arrhythmias, ventricular arrhythmias, hypertrophy, conduction disorders, myocardial infarction or ischemia, pacemaker functions, localization of arrhythmia foci, ECG wave abnormalities, and/or any other disorder). The software does not conduct cardiac analysis and is not intended to replace a standard 12-Lead ECG. The 12-Lead ECG Synthesis Software is intended for adult use only.

          NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

          Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

          The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

          Contact

          IBN

          512.354.7000 Office

          www.InvestorBrandNetwork.com

          Editor@InvestorBrandNetwork.com

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          HeartBeam (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation

          FinanceWire
          HeartBeam
          -3.47%
          Heartbeam, Inc. Warrant
          +3.23%

          Austin, Texas, United States, December 18th, 2025, FinanceWire

          HeartBeam , a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent article that discussed its recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report. “The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in the next generation of cardiac monitoring technology,” reads the article. “HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings. In doing so, HeartBeam is addressing one of modern medicine’s most persistent challenges: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. The company is cleared for arrhythmia today, and ischemia is a future goal.”

          To view the full article, visit https://ibn.fm/3ADRP

          About HeartBeam Inc.

          HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com.

          NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

          Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

          The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

          Contact

          IBN

          512.354.7000 Office

          www.InvestorBrandNetwork.com

          Editor@InvestorBrandNetwork.com

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          Heartbeam Raised to Buy From Speculative Buy by Benchmark

          Dow Jones Newswires
          HeartBeam
          -3.47%
          Heartbeam, Inc. Warrant
          +3.23%

          (13:42 GMT) Heartbeam Price Target Maintained With a $8.00/Share by Benchmark

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.05%

          Investing.com
          Advanced Micro Devices
          -17.31%
          P
          Pom Doctor Ltd.
          -1.28%
          Agape ATP
          +6.33%
          Caterpillar
          -1.57%
          Cboe Global Markets
          +0.94%

          Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Industrials, Basic Materials and Healthcare sectors led shares higher.

          At the close in NYSE, the Dow Jones Industrial Average gained 1.05%, while the S&P 500 index climbed 0.68%, and the NASDAQ Composite index climbed 0.33%.

          The best performers of the session on the Dow Jones Industrial Average were Nike Inc (NYSE:NKE), which rose 3.91% or 2.48 points to trade at 65.81 at the close. Meanwhile, Caterpillar Inc (NYSE:CAT) added 3.53% or 20.99 points to end at 615.35 and Johnson & Johnson (NYSE:JNJ) was up 3.29% or 6.58 points to 206.54 in late trade.

          The worst performers of the session were Microsoft Corporation (NASDAQ:MSFT), which fell 2.78% or 13.70 points to trade at 478.56 at the close. Walmart Inc (NASDAQ:WMT) declined 1.66% or 1.91 points to end at 113.15 and Boeing Co (NYSE:BA) was down 0.82% or 1.65 points to 198.72.

          The top performers on the S&P 500 were GE Vernova LLC (NYSE:GEV) which rose 15.59% to 722.77, Celanese Corporation (NYSE:CE) which was up 7.60% to settle at 43.26 and Western Digital Corporation (NASDAQ:WDC) which gained 7.32% to close at 181.95.

          The worst performers were Uber Technologies Inc (NYSE:UBER) which was down 5.51% to 84.16 in late trade, Netflix Inc (NASDAQ:NFLX) which lost 4.15% to settle at 92.69 and HCA Holdings Inc (NYSE:HCA) which was down 4.05% to 468.73 at the close.

          The top performers on the NASDAQ Composite were Beasley Broadcast Group Inc (NASDAQ:BBGI) which rose 302.17% to 16.69, Heartbeam Inc (NASDAQ:BEAT) which was up 94.29% to settle at 1.57 and Enveric Biosciences Inc (NASDAQ:ENVB) which gained 73.31% to close at 10.26.

          The worst performers were Work Medical Technology Group Ltd (NASDAQ:WOK) which was down 96.59% to 0.19 in late trade, Agape ATP Corp (NASDAQ:ATPC) which lost 94.85% to settle at 0.07 and PomDoctor Ltd ADR (NASDAQ:POM) which was down 90.77% to 0.50 at the close.

          Rising stocks outnumbered declining ones on the New York Stock Exchange by 1925 to 821 and 91 ended unchanged; on the Nasdaq Stock Exchange, 2119 rose and 1266 declined, while 167 ended unchanged.

          Shares in GE Vernova LLC (NYSE:GEV) rose to all time highs; rising 15.59% or 97.47 to 722.77. Shares in Western Digital Corporation (NASDAQ:WDC) rose to all time highs; rising 7.32% or 12.41 to 181.95. Shares in Caterpillar Inc (NYSE:CAT) rose to all time highs; rising 3.53% or 20.99 to 615.35. Shares in Beasley Broadcast Group Inc (NASDAQ:BBGI) rose to 52-week highs; up 302.17% or 12.54 to 16.69. Shares in Work Medical Technology Group Ltd (NASDAQ:WOK) fell to all time lows; down 96.59% or 5.38 to 0.19. Shares in Agape ATP Corp (NASDAQ:ATPC) fell to all time lows; falling 94.85% or 1.25 to 0.07. Shares in PomDoctor Ltd ADR (NASDAQ:POM) fell to all time lows; losing 90.77% or 4.92 to 0.50.

          The CBOE Volatility Index, which measures the implied volatility of S&P 500 options, was down 6.85% to 15.77.

          Gold Futures for February delivery was up 0.49% or 20.75 to $4,256.95 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in January rose 1.17% or 0.68 to hit $58.93 a barrel, while the February Brent oil contract rose 1.11% or 0.69 to trade at $62.63 a barrel.

          EUR/USD was up 0.58% to 1.17, while USD/JPY fell 0.47% to 156.04.

          The US Dollar Index Futures was down 0.56% at 98.64.

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          HeartBeam (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal

          FinanceWire
          HeartBeam
          -3.47%
          Heartbeam, Inc. Warrant
          +3.23%

          Austin, Texas, United States, December 10th, 2025, FinanceWire

          HeartBeam , a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment after successfully appealing a prior NSE determination. The patented cable-free technology captures cardiac electrical signals in three non-coplanar dimensions to generate a synthesized 12-lead ECG that can be reviewed remotely by a board-certified cardiologist, enabling patients to capture meaningful ECG data wherever symptoms occur. With clearance in hand, HeartBeam plans a limited U.S. launch in early 2026 with select cardiology groups, alongside advancing programs in heart attack detection, development of an on-demand 12-lead extended wear patch, and the creation of AI-powered screening and prediction algorithms driven by longitudinal data from its 3D ECG platform.

          To view the full press release, visit https://ibn.fm/36RSg

          About HeartBeam Inc.

          HeartBeam Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.

          (1)Cleared Indications for Use The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient’s 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional.

          The HeartBeam 12-Lead ECG Synthesis Software synthesizes a 12-Lead ECG from the HeartBeam System 3-Leads (in three-directions) recording device, producing a visual 12-Lead ECG representation that is similar, but not identical, to the same leads of a standard diagnostic 12-Lead ECG. The synthesized 12-Lead ECG output is solely intended for manual assessment of normal sinus rhythm and the following non-life-threatening arrhythmias: sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex. The synthesized 12-Lead ECG output is not intended for the assessment of any other arrhythmia or conditions (including but not limited to: other atrial arrhythmias, ventricular arrhythmias, hypertrophy, conduction disorders, myocardial infarction or ischemia, pacemaker functions, localization of arrhythmia foci, ECG wave abnormalities, and/or any other disorder). The software does not conduct cardiac analysis and is not intended to replace a standard 12-Lead ECG. The 12-Lead ECG Synthesis Software is intended for adult use only.

          For full safety information, see the full Instructions for Use or Clinician Portal Manual.

          NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

          Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

          The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

          Corporate Communications

          IBN

          Austin, Texas

          www.InvestorBrandNetwork.com

          512.354.7000 Office

          Editor@InvestorBrandNetwork.com

          Contact

          IBN

          www.InvestorBrandNetwork.com

          Editor@InvestorBrandNetwork.com

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share
          FastBull
          Copyright © 2026 FastBull Ltd

          728 RM B 7/F GEE LOK IND BLDG NO 34 HUNG TO RD KWUN TONG KLN HONG KONG

          TelegramInstagramTwitterfacebooklinkedin
          App Store Google Play Google Play
          Products
          Charts

          Chats

          Q&A with Experts
          Screeners
          Economic Calendar
          Data
          Tools
          Membership
          Features
          Function
          Markets
          Copy Trading
          Latest Signals
          Contests
          News
          Analysis
          24/7
          Columns
          Education
          Company
          Careers
          About Us
          Contact Us
          Advertising
          Help Center
          Feedback
          User Agreement
          Privacy Policy
          Personal Information Protection Statement
          Business

          White Label

          Broker API

          Data API

          Web Plug-ins

          Poster Maker

          Affiliate Program

          Risk Disclosure

          The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.

          No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.

          Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.

          Not Logged In

          Log in to access more features

          Connect Broker
          Become a signal provider
          Help Center
          Customer Service
          Dark Mode
          Price Up/Down Colors

          Log In

          Sign Up

          Position
          Layout
          Fullscreen
          Default to Chart
          The chart page opens by default when you visit fastbull.com